Promega Biotech India & CORE Diagnostics enter into technology collaboration

The collaboration agreement focuses on the implementation of the Promega Microsatellite Instability (MSI) technology for Immuno-Oncology. The patent-protected MSI technology is considered the gold standard molecular assay for detecting DNA mismatch-repair deficiency

0
372
Download PDF
The Promega Team headed by Dr Rajnish Bharti with Ms Zoya Brar, founder, CORE Diagnostics at the later's office in Gurgaon.

New Delhi: Promega Biotech India, a 100 percent subsidiary of Promega Corporation USA, has entered into a technology collaboration with CORE Diagnostics. The collaboration allows CORE Diagnostics to leverage Automated Nucleic Acid Purification with Promega Integrated Quantitation systems. The Maxwell® Automated Nucleic Acid Purification Instrument offers benchtop automation with worry-free, walk-away purification of DNA and RNA from a variety of different sample types.  

The collaboration agreement focuses on the implementation of the Promega Microsatellite Instability (MSI) technology for Immuno-Oncology. The patent-protected MSI technology is considered the gold standard molecular assay for detecting DNA mismatch-repair deficiency.

“We are very pleased that CORE diagnostics and Promega have entered into a collaboration,” said Dr Rajnish Bharti , General Manager at Promega India . “Following our recent discussions with a number of labs, it is clear that they view the Promega MSI assay as an important tool for determining DNA mismatch repair deficiency that is a more straightforward measurement relative to next-generation sequencing. We strongly believe that Promega technologies will be adding substantial value to CORE Diagnostics.”

(L-R) Zoya Brar and Rajnish Bharti shake hands to seal the collaboration on 3rd August. 

Ms Zoya Brar, Founder and Managing Director, CORE Diagnostics, mentioned, “In modern medical science, the role of state-of-the-art diagnostic tools such as nucleic acid purification is of utmost importance and plays a critical role in selecting the most effective clinical intervention. We are constantly innovating in all aspects of service delivery in the underserved high-end diagnostics market.”

On the collaboration with Promega, she added: “We are excited to partner with a global leader in the field of biochemistry, genomics and molecular biology which will help us adapt and be able to scale our capabilities to automating the current sample processing and expand our network to make high-end techniques available to the Indian healthcare market in the best possible way.”

Gurgaon-based CORE Diagnostics brings latest cutting edge testing techniques in areas of definitive diagnosis and Molecular Diagnostics, Flow Cytometry, Immunohistochemistry, Histopathology, Cytogenetics and Cytopathology for patients in India. These tests bring targeted, customized treatment one step closer to reality and can help health practitioners provide the most actionable information to address the various treatment needs of patients in India to get better outcomes.